Nuvation Bio (NYSE:NUVB) received full U.S. FDA approval for its first oncology therapy, Iptrozi, for advanced ROS1-positive non-small cell lung cancer. The company has commercially launched Iptrozi ...
The findings suggest that sequential mutant IDH inhibitor therapy might be one way to fight resistance in metastatic intrahepatic cholangiocarcinoma (IHCC). A new report is shedding light on how some ...
On the heels of a $278 million IPO, Forma Therapeutics is inching toward its first FDA filing. Its lead asset, an IDH1 inhibitor, cleared cancer in one-third of patients with acute myeloid leukemia ...
The addition of ivosidenib (Tibsovo) to azacitidine led to a threefold survival improvement for newly diagnosed IDH1-mutant acute myeloid leukemia (AML) patients who were ineligible for intensive ...
The FDA approved the first targeted therapy for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation. In addition, FDA also approved a companion diagnostic to be used to ...
Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies, justifying a continued Buy rating. RIGL trades at a low P/E of ~7 despite robust 2025 revenue growth ...
Credit: Getty Images. Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with ...
Impact of value frameworks on the magnitude of clinical benefit: Evaluating a decade of randomized trials for systemic therapy in solid malignancies. Effect of enasidenib (ENA) plus azacitidine (AZA) ...
The approval was based on data from the double-blind, placebo-controlled ClarIDHy study. The Food and Drug Administration (FDA) has approved Tibsovo ® (ivosidenib) for the treatment of adult patients ...
A drug used to target IDH1 mutations in select cancers also appears to inhibit the wild-type form of the enzyme, under certain conditions. This feature explains why a large group of different cancers ...
This study reclassified patients according to modern WHO Classification criteria by integrating multi-dimensional molecular markers. It thoroughly investigated the clinical and molecular disparities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results